Clinical Trials and Research - The company plans to initiate a 60-patient clinical trial in the second half of 2026 to validate its oral insulin formulation, aiming for a cost-effective approach to regulatory submissions[26] - The ORA-D-013-1 Phase 3 trial for the oral insulin capsule did not meet its primary or secondary endpoints, leading to a strategic review and a revised Phase 3 trial submission to the FDA[90][91] - The results of the ORA-D-013-1 Phase 3 trial did not meet primary or secondary endpoints, leading to a comprehensive analysis and submission of a new protocol for a Phase 3 clinical trial to the FDA[152] - The ORA-D-013-1 trial did not meet its primary or secondary endpoints, leading to the termination of the ORA-D-013-2 Phase 3 trial[160] - Alpha Tau is conducting five concurrent FDA-approved clinical trials in the U.S. and additional trials in France, Italy, Israel, and planned studies in the UK[52] - The company reported encouraging interim data from a clinical study in Israel combining Alpha DaRT with checkpoint inhibitors for head and neck cancer patients[53] - Alpha Tau anticipates a response from Japan's Ministry of Health regarding its application for Alpha DaRT in recurrent head and neck cancer, which would be its first commercial approval outside of Israel[54] - Alpha Tau is targeting completion of patient recruitment for the ReSTART pivotal trial by Q1 2026 and expects full PMA submission by year-end 2026[58] Financial Transactions and Investments - In the 2023 Scilex Transaction, the company received a senior secured promissory note with a principal amount of $101,875,000, maturing on March 31, 2026, with an interest rate of SOFR plus 8.5%[32] - The company acquired the right to receive 4% royalties on worldwide net sales of ZTLido and related products for 10 years, in exchange for a $2,500,000 reduction in the Tranche A Note[38] - The company participated in a registered direct offering by BioXcel, acquiring shares and warrants for a total consideration of $14,000,000[46] - The company purchased 14,110,121 shares of Alpha Tau Medical Ltd. at a price of $2.612 per share, for an aggregate purchase price of approximately $36,900,000[48] - The company has the right to nominate two directors to Alpha Tau's board and will receive a non-refundable fee of $3,000,000 over three years for providing investor relations services[49] - The company has approved investments of up to $10 million in real estate assets and an additional $20 million, with investments made in various projects including the Rabi Binyamin Project and land in Mevaseret Zion, Israel[180] - The company committed to invest NIS 7,000,000 (approximately $2,185,000) in the Ruby Sapphire II Investment Fund, with NIS 1,556,493 (approximately $499,000) funded as of March 26, 2026[87] - The company has purchased 150,000 shares of Pelthos Therapeutics Inc. for $1,500,000 and currently holds 143,423 shares after selling some[57] - The company has entered into a secured promissory note with Lifeward for $3,000,000 at 15% interest, maturing on May 14, 2026[61] - Lifeward issued shares and warrants to Alpha Tau in exchange for acquiring OraTech, with revenue-sharing payments of 4% from Lifeward's ReWalk products for up to 10 years[66] - The company invested approximately $36.9 million in Alpha Tau, a clinical-stage oncology therapeutics company, with the investment's value dependent on successful clinical results and regulatory approvals[182] Market and Competitive Landscape - The diabetes market is projected to grow from approximately 589 million adults with diabetes in 2024 to 853 million by 2050, highlighting significant market potential[93] - The company faces intense competition in the diabetes treatment sector from established therapeutic options, including GLP-1 receptor agonists[122] - The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and high competition, which may hinder the company's ability to compete[130] - The biotechnology industry is characterized by rapid technological developments and high competition, which may affect the company's ability to recoup R&D expenses[168] Financial Condition and Risks - The company has incurred net losses since inception and currently has only licensing revenues with no product revenues, indicating a challenging path to profitability[146] - The company expects to incur substantial expenditures related to research and development programs, which will be conducted through its strategic evaluation process[142] - The company may require substantial additional financing to implement potential strategic alternatives and continue research and development programs[144] - The company has a history of losses and cannot assure future operating results, with no products expected to be on the market for several years[146] - The company may face significant operational and financial risks if a strategic transaction is pursued, including increased expenditures and potential litigation[138] - The company may need to delay or scale back its research and development programs if adequate financing is not secured[145] - The company is dependent on third-party suppliers for raw materials and services, which poses risks to its operations[130] - The company is dependent on third-party suppliers for oral insulin capsules and lacks long-term agreements for supply[161] - The approval process for new drugs can take several months to years, with an average review lasting 18 months[116] Corporate Governance and Compliance - The company has contracted with thirteen individuals for employment or consulting arrangements, with a focus on retaining top talent[125] - The company must maintain compliance with Nasdaq listing requirements, including a minimum bid price of $1.00 per share, to avoid delisting[191] - The company has implemented anti-takeover Rights that may discourage favorable acquisitions, potentially causing substantial dilution to unauthorized acquirers[215] - Delaware law may complicate or delay changes in control or acquisitions, even if they are in the best interests of stockholders[217] - The company prioritizes cybersecurity, with measures including firewalls, intrusion detection systems, and access controls to mitigate risks[220] - The Chief Operating and Business Officer is responsible for cybersecurity protection measures and incident response[221] - The company maintains compliance programs to address potential cyber-security breaches, which could materially affect its financial position if not managed effectively[210] External Factors and Economic Conditions - The company is subject to political, economic, and military risks due to its operations in Israel, which could negatively impact its business[199] - Recent political events have led to a downgrade of Israel's credit rating from A1 to A2 in October 2023, and further to Baa1 with a negative outlook in September 2024[204] - The company is exposed to currency exchange rate fluctuations, with significant expenses in non-dollar currencies affecting financial results, particularly with the dollar's depreciation against the NIS in 2025[178] Shareholder Considerations - Stockholders may experience significant dilution if the company raises additional funds by issuing equity securities[197] - The company anticipates needing to raise capital through equity offerings, which may adversely affect the trading price of its common stock[196] - The company has outstanding 40,446,179 shares of common stock as of March 26, 2026, which could be affected by future sales from existing stockholders[189] - The company experienced a significant decline in stock price following the announcement of the ORA-D-013-1 Phase 3 trial results in January 2023[195] - The management has significant flexibility in using the net proceeds from any securities offerings, which could impact the company's future financial health[211]

Core Insights - Lifeward Ltd. has successfully closed a strategic partnership agreement with Oramed Pharmaceuticals, enhancing its position as a diversified biomedical innovation company with a clear path to profitability [1][2] Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1][3] - The company designs, develops, and commercializes solutions that provide functional and health benefits in both clinical and home settings [3] - Lifeward's product portfolio includes notable innovations such as the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit [3] Strategic Partnership Details - The partnership with Oramed Pharmaceuticals includes the acquisition of Oramed's clinical-stage Protein Oral Delivery (POD™) technology, which opens up significant opportunities in the biotech market [2] - Lifeward has access to up to $47 million in capital from Oramed and other investors, having accessed $10 million of this capital on March 25, 2026 [2] Operational Changes - Following the partnership, Lifeward has made changes to its board of directors, indicating a strategic shift in governance to align with its new objectives [2]

Core Insights - Lifeward is positioned as a diversified biomedical innovation company with a clear path to profitability through its strategic partnership with Oramed Pharmaceuticals, integrating Oramed's POD™ oral delivery technology [1][2][3] Financial Aspects - The partnership allows Lifeward access to up to $47 million in capital through various funding mechanisms, including equity and milestone-based funding [3][4] - Lifeward aims to drive profitability from its established medical technology product portfolio while investing in complementary technologies [4][8] Strategic Opportunities - The integration of the POD™ platform provides Lifeward exposure to a significant biotechnology market, particularly in oral delivery of biologic drugs, which could transform treatment for chronic diseases [5][6] - The POD™ technology has been evaluated in clinical programs for diabetes, a market exceeding $80 billion annually, indicating substantial growth potential [6][7] Operational Focus - Oramed will manage and fund the clinical development of the POD™ platform, allowing Lifeward to concentrate on its existing MedTech business while benefiting from the biotechnology platform's potential [7][8] - Lifeward's strategy includes building a diversified biomedical portfolio that balances immediate revenue generation with long-term innovation opportunities [13]

Core Insights - Lifeward is positioning itself as a MedTech platform with a clear path to profitability and long-term Biotech potential through a strategic partnership with Oramed Pharmaceuticals [1][2] Investment and Financial Structure - Lifeward will receive up to $47 million in strategic investment from Oramed and another investor, which includes equity, convertible notes, milestone-based funding, and warrant coverage [2][14] - The investment structure aims to support Lifeward's journey to profitability while allowing for selective investments in high-value innovations [2] Technology Acquisition - Lifeward is acquiring Oramed's Protein Oral Delivery (POD™) technology, which targets the $600+ billion injectable drugs market, including the potential for ORMD-0801 to become the first commercialized oral insulin [1][3] - The POD™ technology is designed to transform injectable biological therapies into oral medications, addressing a significant market opportunity in diabetes and other metabolic diseases [3][10] Clinical Development and Management - Oramed will manage and fund the clinical development of the POD™ technology, allowing Lifeward to focus on profitability and cash generation while retaining exposure to biotech opportunities [4][8] - The POD™ technology has shown promise in clinical trials, with the lead drug candidate ORMD-0801 achieving significant results in reducing HbA1c levels [12] Strategic Goals and Diversification - The partnership with Oramed marks the beginning of Lifeward's broader diversification strategy across medical technology and biotechnology [5] - Lifeward aims to achieve sustainable profitability from existing FDA-approved products while building a balanced biomedical portfolio that combines near-term revenue with long-term biotech innovation [6][7]

Core Viewpoint - The strategic transaction between Oramed Pharmaceuticals and Lifeward involves the transfer of Oramed's proprietary Protein Oral Drug (POD™) delivery technology to Lifeward, positioning Oramed as a significant shareholder with a 49.9% beneficial ownership interest in Lifeward [2][3][4] Transaction Overview - Oramed will transfer its POD™ technology to Lifeward, which will result in Oramed obtaining a 49.9% beneficial ownership interest in Lifeward, along with warrants [5][6] - Lifeward will issue $10 million in senior secured convertible notes in a private placement, with Oramed investing $9 million, and an additional milestone-based $10 million note, also with Oramed investing $9 million, both having 100% warrant coverage [2][14] Strategic Vision - The transaction is seen as a strategic evolution for Oramed, allowing it to maintain exposure to oral drug delivery innovation while participating in a medical robotics company poised for significant growth [3][4] - Lifeward's acquisition of the POD™ technology is expected to enhance its capabilities in advancing oral insulin programs and diversifying its biomedical innovation portfolio [4][6] Leadership and Management - Lifeward's leadership under President and CEO Mark Grant, who has over 25 years of experience in healthcare and medical technology, is expected to drive the advancement of the newly acquired oral drug delivery platform [4][6] - Oramed will manage the upcoming anticipated clinical trial related to the POD™ technology [3][7] Financial Performance - Lifeward's FDA-approved products, ReWalk® and AlterG®, generated $26 million in revenue over the last four quarters, indicating a solid financial foundation for the company [6]

Group 1 - Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, fulfilling obligations under the Option Agreement, resulting in total returns of $118 million on a $99.5 million investment [1][2] - Oramed retains a $27 million note and a $12 million convertible note with Scilex, convertible into equity at $36 per share, with repayment scheduled through October 2026 if not converted [2] - The Board of Directors approved a cash dividend of $0.25 per share, with an expected total distribution of approximately $10.5 million, funded by surplus capital [3] Group 2 - Oramed is a clinical-stage pharmaceutical company focused on oral delivery solutions for injectable drugs, utilizing its Protein Oral Delivery (POD™) technology [4]

Group 1 - The article discusses the investment insights and strategies of a writer focused on Long/Short investment ideas in North America [1] - The writer has a background in finance and economics, holding a Master's degree from Queen Mary University of London and a Bachelor's degree from Middlesex University [1] Group 2 - The article does not provide specific company or industry analysis, nor does it include any financial data or performance metrics [2][3]

Share Repurchase and Financial Management - On October 20, 2025, Oramed Pharmaceuticals Inc. repurchased 1,155,367 shares at a price of $2.23 per share, totaling $2,576,468.41[4] - The repurchase agreement reflects the company's commitment to managing its capital structure effectively[4] - The share repurchase and termination of the joint venture are part of the company's strategic adjustments in response to market conditions[4][7] Joint Venture and Strategic Decisions - The company terminated its Joint Venture Agreement with HTIT Biotech due to unmet closing conditions, effective October 23, 2025[7] - The company continues to explore opportunities for market expansion and new product development despite recent challenges[7] Financial Information and Cautionary Notes - Preliminary financial information as of September 30, 2025, was issued in a Shareholder Letter, but it is unaudited and subject to future adjustments[8] - The company cautioned that the financial information provided should not be relied upon for investment decisions, as it may materially vary from actual results[9] - The company has not completed its quarter-end financial close processes, indicating potential changes in reported results[9] - The financial information disclosed is based on management's estimates and assumptions, highlighting the preliminary nature of the data[9] Business Strategy Focus - The company remains focused on its oral drug delivery technology as a core aspect of its business strategy[6]

Core Insights - Oramed Pharmaceuticals Inc. reported a strong financial performance for the nine months ended September 30, 2025, with total assets increasing by 42% to $220.5 million [1][7] - The company achieved a net income of $65 million, a significant turnaround from a net loss of $6.1 million in the same period last year, primarily due to cash returns from Scilex Holding Company and unrealized gains from investments in Alpha Tau Medical Ltd. [3][4][7] Financial Highlights - Net income (pre-tax) reached $65.0 million, compared to a net loss of $6.1 million in the same period last year [7] - The company completed a full repayment from Scilex, receiving approximately $27 million during the period, totaling $100 million in principal return from this strategic investment [4][7] - Basic earnings per share were reported at $1.30, while diluted earnings per share were $1.26 [7] - Total assets grew from $155.3 million to $220.5 million year-over-year, marking a 42% increase [7] - Research and Development (R&D) expenses decreased from $4.9 million to $4.4 million, while General and Administrative (G&A) expenses increased from $4.3 million to $5.0 million [7] Management Commentary - CEO Nadav Kidron emphasized that the disciplined investment strategy is yielding strong results, providing the company with greater financial flexibility to pursue strategic opportunities while advancing its oral drug delivery platform [4]

Core Viewpoint - Oramed Pharmaceuticals Inc. has adopted a Rights Agreement to protect stockholders in the event of a hostile takeover, ensuring fair treatment and enhancing negotiation power with potential acquirers [1][3]. Group 1: Rights Agreement Details - The Rights Agreement, effective November 17, 2025, grants stockholders one common stock purchase right for each share held, aimed at preventing unfair takeover tactics [1][2]. - Each Right allows stockholders to purchase one share of Common Stock at a price of $10.00, becoming exercisable if a person or group acquires 15% or more of the outstanding shares [2][3]. - The Rights will expire three years after adoption unless redeemed or exchanged earlier by the Company [4]. Group 2: Rights Exercise and Redemption - Upon triggering the ownership threshold, each Right can be exercised for shares or equivalent value, but Rights held by the triggering person will become void [3]. - The Board of Directors retains the option to redeem the Rights at $0.012 per Right before any person becomes an Acquiring Person [2][3]. Group 3: Dividend Distribution - The dividend distribution of the Rights will be payable on November 27, 2025, to stockholders of record as of the close of business on that date [4]. - The distribution of Rights is not taxable to stockholders [4]. Group 4: Company Overview - Oramed Pharmaceuticals Inc. is a pioneer in oral delivery solutions for drugs typically administered via injection, utilizing its Protein Oral Delivery (POD™) technology to enhance drug absorption [5].